"Carbamates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of carbamic acid, H2NC(=O)OH. Included under this heading are N-substituted and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes, and polymers that include repeating units of carbamate are referred to as POLYURETHANES. Note however that polyurethanes are derived from the polymerization of ISOCYANATES and the singular term URETHANE refers to the ethyl ester of carbamic acid.
| Descriptor ID |
D002219
|
| MeSH Number(s) |
D02.241.081.251
|
| Concept/Terms |
Carbamic Acids- Carbamic Acids
- Acids, Carbamic
- Aminoformic Acids
- Acids, Aminoformic
|
Below are MeSH descriptors whose meaning is more general than "Carbamates".
Below are MeSH descriptors whose meaning is more specific than "Carbamates".
This graph shows the total number of publications written about "Carbamates" by people in this website by year, and whether "Carbamates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 18 | 36 | 54 |
| 2018 | 19 | 28 | 47 |
| 2019 | 7 | 12 | 19 |
| 2020 | 2 | 2 | 4 |
| 2021 | 4 | 3 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Carbamates" by people in Profiles.
-
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol. 2021 12; 93(12):6750-6759.
-
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight. Biochem Biophys Res Commun. 2021 09 24; 571:26-31.
-
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2021 07 15; 76(8):2158-2167.
-
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther. 2022 02; 20(2):291-295.
-
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021 Oct; 54(5):767-775.
-
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2021 06 23; 78(13):1184-1194.
-
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021 06 18; 76(7):1874-1885.
-
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. Anticancer Drugs. 2021 06 01; 32(5):589-591.
-
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase. Sci Rep. 2021 05 13; 11(1):10290.
-
[Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.] Recenti Prog Med. 2021 04; 112(4):49e-52e.